August 28, 2019
Biopharmaceutical company Pfizer has announced a $500-million investment for the construction of a gene therapy manufacturing facility in Sanford, NC. The facility will support Pfizer’s continuing investment in gene therapy research and development, similar to its R&D sites in Chapel Hill and Kit Creek.
The expanded facility is projected to add approximately 300 new jobs. Pfizer currently employs 650 people at the Sanford site, which is used mainly to manufacture late stage pipeline drugs for Duchenne muscular dystrophy (DMD) and hemophilia B.
“This investment will further strengthen Pfizer’s leadership in gene therapy manufacturing technology,” said Mike McDermott, President, Pfizer Global Supply. “The expansion of the Sanford site is expected to create hundreds of highly skilled jobs, which would increase Sanford’s high-tech manufacturing environment and is part of our overall plan to invest approximately $5 billion in U.S.-based capital projects over the next several years.”
For comments, questions or concerns, please contact David Cohen